<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PARICALCITOL</span><br/>(par-i-cal'ci-tol)<br/><span class="topboxtradename">Zemplar<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">vitamin d analog</span><br/><b>Prototype: </b>Calcitriol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mcg/mL vial; 1 mcg, 2 mcg, 4 mcg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic vitamin D analog that reduces parathyroid hormone activity (PTH) levels in chronic kidney failure (CRF) patients.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers serum levels of calcium and phosphate; serum calcium times serum phosphate cross product value may increase. In addition
         it decreases the parathyroid hormone as well as bone resorption in some patients. Indicated by iPTH levels 
      </p><h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of secondary hyperparathyroidism associated with CRF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to paricalcitol; hypercalcemia; evidence of vitamin D toxicity; concurrent administration of phosphate preparations
         and vitamin D; pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; severe liver disease; concurrent administration of digitalis; abnormally low levels of PTH.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CHF-Associated Secondary Hyperparathyroidism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.04 mcg/kg0.1 mcg/kg (max: 24 mcg/kg), no more than every other day during dialysis <span class="rdroute">PO</span> iPTH 500 pg/mL, 2 mcg/d or 4 mcg 3 times/wk<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>517 y,</i> 0.04 mcg/kg 3 times/wk during dialysis<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give no more frequently than every other day when dosing 3 times/wk.</li>
<li>Store at 1530° C (5986° F).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give IV bolus dose anytime during dialysis.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 25° C (77° F). Discard unused portion of a single dose vial.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Chills, feeling unwell, fever, flu-like symptoms, sepsis, edema. <span class="typehead">CNS:</span> Lightheadedness. <span class="typehead">CV:</span> Palpitations. <span class="typehead">GI:</span> Dry mouth, <span class="speceff-life">GI bleeding</span>, <span class="speceff-common">nausea,</span> vomiting. <span class="typehead">Respiratory:</span> Pneumonia. <span class="typehead">Metabolic:</span> Hypercalcemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Hypercalcemia may increase risk of <b>digoxin</b> toxicity; may increase <b>magnesium</b> absorption and toxicity in renal failure. <span class="typehead">Herbal:</span> Be cautious of <b>Vitamin D</b> content in herbal and OTC products. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Elimination:</span> Excreted primarily in feces (74%). <span class="typehead">Half-Life:</span> 15 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypercalcemia (see Appendix F).</li>
<li>Lab tests: Serum calcium and phosphate 2 times a wk during initiation of therapy; then monthly; serum PTH q3mo; periodic serum
            magnesium, alkaline phosphatase, 24-urinary calcium and phosphate. Increase frequency of lab tests during dosage adjustments.
         </li>
<li>Withhold drug and notify physician if hypercalcemia occurs.</li>
<li>Coadministered drugs: Monitor for digoxin toxicity if serum calcium level is elevated.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following to the physician: Weakness, anorexia, nausea, vomiting, abdominal cramps, diarrhea,
            muscle or bone pain, or excessive thirst.
         </li>
<li>Adhere strictly to dietary regimen of calcium supplementation and phosphorus restriction to ensure successful therapy.</li>
<li>Avoid excessive use of aluminum-containing compounds such as antacids/vitamins.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>